May 23rd In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Viking Therapeutics (NASDAQ: VKTX), with a price target of $5. McCarthy commented, “Hip fracture, and in particular the associated recovery, represents an unmet medical need. VK5211 could be the first approved therapy (SARM [selective androgen receptor modulator]) for patients recovering from non-elective hip- fracture surgery.
So typical isn't it? How anybody pays them for their drivel is beyond me. They're always saying "buy" at the top and "sell" at the bottom. They're pathetic along with the sheep that actually listen to them.